Premium
Improved Blood Glucose Control by Insulin Therapy in Type 2 Diabetic Patients Has No Effect on Lipoprotein(a) Levels
Author(s) -
Wolffenbuttel B.H.R.,
Leurs P.B.,
Sels J.P.J.E.,
RondasColbers G.J.W.M.,
Menheere P.P.C.A.,
Kruseman A.C. Nieuwenhuijzen
Publication year - 1993
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/j.1464-5491.1993.tb00093.x
Subject(s) - medicine , endocrinology , insulin , diabetes mellitus , apolipoprotein b , lipoprotein , lipoprotein(a) , body mass index , type 2 diabetes , cholesterol , metabolic control analysis , blood lipids , apolipoprotein a1
The effects of improved blood glucose control by insulin therapy on lipoprotein(a) and other lipoproteins were studied in 54 patients with Type 2 diabetes (mean ± SD: age 67 ± 9 years, body mass index 26.1 ± 4.4 kg m −2 , median duration of diabetes 10 (range 1–37) years, 23 males, 31 females), who were poorly controlled despite diet and maximal doses of oral hypoglycaemic agents. After 6 months of insulin treatment, mean fasting blood glucose concentrations had decreased from 14.1 ± 2.2 mmol l −1 to 8.4 ± 1.8 mmol l −1 ( p < 0.001), and HbA 1c had fallen from 11.1 ± 1.4 % to 8.2 ± 1.1 % ( p < 0.001). Significant decreases of total and LDL cholesterol, triglycerides, apolipoprotein B, and free fatty acids were observed, while HDL‐cholesterol and apoA1 increased by 10 %. Baseline serum Lp(a) levels were elevated compared to non‐diabetic subjects of similar age (median 283, range 8–3050 mg I −1 , vs 101, range 8–1747 mg I −1 , p < 0.05), but did not change with insulin, and there was no correlation with the degree of metabolic improvement and changes in Lp(a) levels. It is concluded that improved blood glucose control by insulin therapy does not alter elevated Lp(a) levels in Type 2 diabetic patients, but has favourable effects on the other lipoproteins.